Anuradha Banerjee MD
Associate Clinical Professor of Pediatrics and Neurological Surgery
Pediatric Neuro-oncologist
Dr. Banerjee is a pediatrician with fellowship training in pediatric hematology and oncology. She is also an epidemiologist and has a special interest in pediatric palliative care. She currently works with Dr. Michael Prados in Pediatric Brain Tumor Consortium clinical trials. Dr. Banerjee's research at present involves the use of novel convection-enhanced delivery of novel drugs for treatment of high-grade glioma, and the role of signal transduction inhibitors with radiation for the treatment of brainstem glioma.
Education, Training, and Previous Positions
- 1987: BA, Stanford University
- 1996: BA, Harvard University
- 1990: MPH, Tulane School of Public Health
- 1992: MD, Tulane School of Medicine
- 1992-1996: Residency in Pediatrics, UCSF
- 1999-2001: Assistant Clinical Professor of Pediatrics, UCSF
- 2001-Present: Department of Neurological Surgery, UCSF
Selected Professional Memberships and Appointments
- American Association for Cancer Research
- American Society of Clinical Oncology
- Children's Oncology Group
- Pediatric Brain Tumor Consortium
- Society for Neuro-Oncology
- The American Society of Pediatric Hematology/Oncology
Selected Recent Publications
McBride SM, Daganzo SM, Banerjee A, Gupta N, Lamborn KR, Prados MD, Berger MS, Wara WM, Haas-Kogan DA. Radiation is an Important Component of Multimodality Therapy for Pediatric Non-Pineal Supratentorial Primitive Neuroectodermal Tumors [published online ahead of print May 15, 2008]. Int J Radiat Oncol Biol Phys. doi:10.1016/j.ijrobp.2008.03.033
Haas-Kogan DA, Banerjee A, Kocak M, Prados MD, Geyer JR, Fouladi M, McKnight T, Poussaint TY, Broniscer A, Blaney SM, Boyett JM, Kun LE. Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma. Neuro Oncol 2008;10(3):341-7.
Pang J, Banerjee A, Tihan T. The value of tandem CSF/MRI evaluation for predicting disseminated disease in childhood central nervous system neoplasms. J Neurooncol 2008;87(1):97-102.
Kieran MW, Packer RJ, Onar A, Blaney SM, Phillips P, Pollack IF, Geyer JR, Gururangan S, Banerjee A, Goldman S, Turner CD, Belasco JB, Broniscer A, Zhu Y, Frank E, Kirschmeier P, Statkevich P, Yver A, Boyett JM, Kun LE. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. J Clin Oncol 2007;25(21):3137-43.
Pollack IF, Jakacki RI, Blaney SM, Hancock ML, Kieran MW, Phillips P, Kun LE, Friedman H, Packer R, Banerjee A, Geyer JR, Goldman S, Poussaint TY, Krasin MJ, Wang Y, Hayes M, Murgo A, Weiner S, Boyett JM. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol 2007;9(2):145-60.
Mishra KK, Puri DR, Missett BT, Lamborn KR, Prados MD, Berger MS, Banerjee A, Gupta N, Wara WM, Haas-Kogan DA. The role of up-front radiation therapy for incompletely resected pediatric WHO grade II low-grade gliomas. Neuro Oncol 2006;8(2):166-74.
Etzell JE, Keet C, McDonald W, Banerjee A. Medulloblastoma simulating acute myeloid leukemia: case report with a review of "myeloid antigen" expression in nonhematopoietic tissues and tumors [Review]. J Pediatr Hematol Oncol 2006;28(11):703-10.
